Nucleic Acids Research Advance Access published online on September 10, 2009
Nucleic Acids Research, doi:10.1093/nar/gkp723
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Regulation, Chromatin and Epigenetics |
MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines
1Department of Morphological and Biomedical Sciences, Section of Biochemistry and 2Department of Pathology, University of Verona, Verona, Italy
*To whom correspondence should be addressed. Tel: +39 045 8027169; Fax: +39 045 8027170; Email: marta.palmieri{at}univr.it
Received January 24, 2008. Revised August 11, 2009. Accepted August 16, 2009.
The aim of the present study was to analyse the molecular mechanisms involved in the Interleukin-6 (IL-6) silencing in pancreatic adenocarcinoma cell lines. Our results demonstrate that TNF-
, a major IL-6 inducer, is able to induce IL-6 only in three out of six cell lines examined. 5-aza-2'-deoxycytidine (DAC), but not trichostatin A (TSA), activates the expression of IL-6 in all cell lines, indicating that DNA methylation, but not histone deacetylation, plays an essential role in IL-6 silencing. Indeed, the IL-6 upstream region shows a methylation status that correlates with IL-6 expression and binds MeCP2 and H3meK9 only in the non-expressing cell lines. Our results suggest that critical methylations located from positions –666 to –426 relative to the transcription start site of IL-6 may act as binding sites for MeCP2.